Cargando…

LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas

PURPOSE: Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to promote the malignant behavior of tumors. LASP1...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderheijden, Cas, Vaessen, Thomas, Yakkioui, Youssef, Riedl, Robert, Temel, Yasin, Hovinga, Koos, Hoogland, Govert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166821/
https://www.ncbi.nlm.nih.gov/pubmed/35507100
http://dx.doi.org/10.1007/s11060-022-04012-9
_version_ 1784720692122484736
author Vanderheijden, Cas
Vaessen, Thomas
Yakkioui, Youssef
Riedl, Robert
Temel, Yasin
Hovinga, Koos
Hoogland, Govert
author_facet Vanderheijden, Cas
Vaessen, Thomas
Yakkioui, Youssef
Riedl, Robert
Temel, Yasin
Hovinga, Koos
Hoogland, Govert
author_sort Vanderheijden, Cas
collection PubMed
description PURPOSE: Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to promote the malignant behavior of tumors. LASP1 was previously identified as a possibly overexpressed protein in a chordoma proteomics experiment. In this study we compare LASP1 expression in chordoma and chondrosarcoma tissue. METHODS: Biopsies of primary tumors were collected from surgically treated chordoma (n = 6) and chondrosarcoma (n = 6) patients, flash-frozen upon collection and collectively analyzed for LASP1 RNA (real-time PCR) and protein expression (western blotting). Additionally, tissue micro array (TMA)-based immunohistochemistry was applied to an archive of 31 chordoma and 1 chondrosarcoma specimen. RESULTS: In chordoma samples, LASP1 mRNA was detected in 4/6 cases and a strong 36 kDa immunoreactive protein band was observed in 4/5 cases. In contrast, 0/6 chondrosarcoma samples showed detectable levels of LASP1 mRNA and only a weak 36 kDa band was observed in 4/5 cases. Immunohistochemical analysis showed LASP1 expression in all chordoma samples, whereas chondrosarcoma specimen did not show immunoreactivity. CONCLUSION: LASP1 is strongly expressed in the majority of chordoma cases and shows low expression in chondrosarcoma tissue. Since LASP1 is known to function as oncogene and regulate cell proliferation in other tumor types, this study implicates a role for LASP1 in chordoma biology. Further studies are warranted to improve understanding of LASP1’s expression and functioning within chordoma, both in vitro and in vivo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04012-9.
format Online
Article
Text
id pubmed-9166821
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-91668212022-06-05 LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas Vanderheijden, Cas Vaessen, Thomas Yakkioui, Youssef Riedl, Robert Temel, Yasin Hovinga, Koos Hoogland, Govert J Neurooncol Laboratory Investigation PURPOSE: Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to promote the malignant behavior of tumors. LASP1 was previously identified as a possibly overexpressed protein in a chordoma proteomics experiment. In this study we compare LASP1 expression in chordoma and chondrosarcoma tissue. METHODS: Biopsies of primary tumors were collected from surgically treated chordoma (n = 6) and chondrosarcoma (n = 6) patients, flash-frozen upon collection and collectively analyzed for LASP1 RNA (real-time PCR) and protein expression (western blotting). Additionally, tissue micro array (TMA)-based immunohistochemistry was applied to an archive of 31 chordoma and 1 chondrosarcoma specimen. RESULTS: In chordoma samples, LASP1 mRNA was detected in 4/6 cases and a strong 36 kDa immunoreactive protein band was observed in 4/5 cases. In contrast, 0/6 chondrosarcoma samples showed detectable levels of LASP1 mRNA and only a weak 36 kDa band was observed in 4/5 cases. Immunohistochemical analysis showed LASP1 expression in all chordoma samples, whereas chondrosarcoma specimen did not show immunoreactivity. CONCLUSION: LASP1 is strongly expressed in the majority of chordoma cases and shows low expression in chondrosarcoma tissue. Since LASP1 is known to function as oncogene and regulate cell proliferation in other tumor types, this study implicates a role for LASP1 in chordoma biology. Further studies are warranted to improve understanding of LASP1’s expression and functioning within chordoma, both in vitro and in vivo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04012-9. Springer US 2022-05-04 2022 /pmc/articles/PMC9166821/ /pubmed/35507100 http://dx.doi.org/10.1007/s11060-022-04012-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Laboratory Investigation
Vanderheijden, Cas
Vaessen, Thomas
Yakkioui, Youssef
Riedl, Robert
Temel, Yasin
Hovinga, Koos
Hoogland, Govert
LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title_full LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title_fullStr LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title_full_unstemmed LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title_short LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas
title_sort lim and sh3 protein 1 (lasp1) differentiates malignant chordomas from less malignant chondrosarcomas
topic Laboratory Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166821/
https://www.ncbi.nlm.nih.gov/pubmed/35507100
http://dx.doi.org/10.1007/s11060-022-04012-9
work_keys_str_mv AT vanderheijdencas limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT vaessenthomas limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT yakkiouiyoussef limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT riedlrobert limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT temelyasin limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT hovingakoos limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas
AT hooglandgovert limandsh3protein1lasp1differentiatesmalignantchordomasfromlessmalignantchondrosarcomas